Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2026 10:00 ET | Quelle: BendPak

Tall Vehicles, Low Ceilings No Problem with New BendPak 12APF Two-Post Lift

Service cars, SUVs, work trucks and vans up to 12,000 lbs. in low-ceiling bays with new ALI-Certified BendPak 12APF open-top two-post lift.
31. März 2026 09:00 ET | Quelle: Citeline

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Citeline, a leader in clinical solutions for the life sciences, announced an expanded strategic partnership with Recursion, a leading tech-bio company.
31. März 2026 08:45 ET | Quelle: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and...
31. März 2026 08:35 ET | Quelle: Ambros Therapeutics, Inc.

Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new...
31. März 2026 08:00 ET | Quelle: Imunon, Inc.

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...
31. März 2026 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
31. März 2026 06:00 ET | Quelle: ThinkLabs AI

ThinkLabs AI Closes $28 M Series A Led by Energy Impact Partners, Backed by NVentures and Edison International

New York, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- ThinkLabs, an AI-powered grid intelligence company that empowers critical infrastructure with trustworthy, physics-informed AI, announced today...
31. März 2026 03:38 ET | Quelle: Trifork Group AG

Trifork Digital Health expands into new markets with engagements in Canada and Germany

Press ReleaseDanish version attached Trifork Digital Health expands into new markets with engagements in Canada and Germany Aarhus, Denmark – March 31, 2026 Trifork Digital Health is expanding its...
31. März 2026 02:45 ET | Quelle: Standing Ovation

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Standing Ovation, a French precision fermentation pioneer producing next-generation proteins, has announced a $34.2 million (€30 million) Series B round.
31. März 2026 01:30 ET | Quelle: ONWARD Medical NV

ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) --...

Vorherige Seite

Nächste Seite